AAV-mediated miR-103A-3P inhibition

AAV-mediated miR-103A-3P inhibition has been studied in 1 paper since 2026: none in people yet, 1 in cells; 1 in the past year. No study of it in people or animals has been published yet. The newest story, Nov 6, 2026: “Immune-cell packages impair energy production in lab-grown cells”.

Intervention

1 paper studies it1 findingUpdated Nov 5, 2026

1 new paper in 30 daysSee all 1 papers on AAV-mediated miR-103A-3P inhibition

At a glance

The findings reach mice, none yet in people. 1 lab.

1 lab

Cells1

What did studies of AAV-mediated miR-103A-3P inhibition find?

Studies of AAV-mediated miR-103A-3P inhibition measured 1 outcome; the most studied are ovarian function (1 study).

Ovarian function

upin mice1

1 study

AAV-mediated miR-103A-3P inhibition improves ovarian function in mice.
“In vivo, AAV‐mediated inhibition of miR‐103a‐3p improved follicular development and ovarian function.”
Animalsovary
Immune-cell packages impair energy production in lab-grown cells
Aging cellNov 5, 2026

Latest

1 paper in 12 months

Aging CellNov 6

Immune-cell packages impair energy production in lab-grown cells

Experiments in lab-grown ovarian cells found that packages from dying immune cells disrupted energy production; inhibiting a small RNA molecule eased the effects.Experiments in lab-grown ovarian cells found that packages from dying immune cells disrupted energy production; inhibiting a small RNA molecule eased the effects.

Human cell studyBlood and immune system

Paper